A transfusion related adverse event attributed to IgA2 driven complement activation is observed in two Fabry disease patients given α-galactosidase based enzyme replacement therapy

Molecular Genetics and Metabolism 2026

View at publisher

Authors: Wendy Heywood, Tomas Baldwin, David Moreno-Martínez, Uma Ramaswami, Kevin A. Mills, Derralynn A. Hughes

DOI: 10.1016/j.ymgme.2025.109462

Cited by: 0

Fields of Study & Subjects

Lysosomal Storage Disorders Research Complement system in diseases Blood transfusion and management